2003
Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials
ARNOLD L, VITIELLO B, MCDOUGLE C, SCAHILL L, SHAH B, GONZALEZ N, CHUANG S, DAVIES M, HOLLWAY J, AMAN M, CRONIN P, KOENIG K, KOHN A, MCMAHON D, TIERNEY E. Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials. Journal Of The American Academy Of Child & Adolescent Psychiatry 2003, 42: 1443-1450. PMID: 14627879, DOI: 10.1097/00004583-200312000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAggressionAutistic DisorderChildClinical Trials as TopicDopamine AntagonistsDouble-Blind MethodEndpoint DeterminationFemaleHumansMaleObserver VariationParent-Child RelationsPlacebosResearch DesignRisperidoneSeverity of Illness IndexStereotyped BehaviorTreatment OutcomeConceptsAberrant Behavior Checklist-Irritability subscaleClinical trialsIrritability subscaleClinical Global Impression-ImprovementDouble-blind trialPediatric Psychopharmacology Autism NetworkChief complaintCommon symptomsTarget symptomsEfficacy assessmentIrritable behaviorSymptom categoriesRisperidoneChange scoresSymptomsEffect size dInterrater reliabilityTrialsPlaceboTreatment effectsClinical applicationPrimary measureConsumer-friendly wayWeeksAutism Network
1999
Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder
Martin A, Koenig K, Scahill L, Bregman J. Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder. Journal Of Child And Adolescent Psychopharmacology 1999, 9: 99-107. PMID: 10461820, DOI: 10.1089/cap.1999.9.99.Peer-Reviewed Original ResearchConceptsClinical Global Impression ScaleTreatment of childrenSide effectsAutistic disorderOpen-label trialShort-term safetyWeeks of treatmentGlobal Impression ScaleGlobal improvement itemSignificant side effectsSerious side effectsDSM-IV criteriaFurther dose increasesLack of responseMean ageImpression ScalePossible seizuresMale subjectsWeight gainBehavioral activationFourth weekQuetiapine fumarateDose increaseClinical populationsWeeks